Eisai is withdrawing weight-loss drug lorcaserin after a post-marketing study found a higher incidence of cancer in patients who took the medicine.

The FDA said Thursday that its request for removal of the product from the market is voluntary, but Eisai has already started the process for doing so. The withdrawal follows an FDA alert issued last month that lorcaserin may contribute to a higher risk of cancer.

Lorcaserin was approved in 2012 as a weight management therapy for use in addition to a reduced-calorie diet and exercise. The drug was intended to suppress appetite while avoiding risks of heart problems… Read more »